Novartis announces positive data from phase III study of intrathecal onasemnogene abeparvovec in broad patient population with SMA: Basel Friday, March 21, 2025, 11:00 Hrs [IST] N ...
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...
The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.
Primary care clinicians are often the most accessible to patients and play a crucial role in the early detection and ...
Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.
An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback